- Home
- ALRS vs ERAS Comparison
ALRS vs ERAS Comparison
Compare ALRS & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALRS
- ERAS
- Stock Information
- Founded
- ALRS 1879
- ERAS 2018
- Country
- ALRS United States
- ERAS United States
- Employees
- ALRS N/A
- ERAS N/A
- Industry
- ALRS Major Banks
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- ALRS Finance
- ERAS Health Care
- Exchange
- ALRS Nasdaq
- ERAS Nasdaq
- Market Cap
- ALRS 572.8M
- ERAS 484.4M
- IPO Year
- ALRS 2019
- ERAS 2021
- Fundamental
- Price
- ALRS $21.60
- ERAS $1.64
- Analyst Decision
- ALRS Hold
- ERAS Strong Buy
- Analyst Count
- ALRS 5
- ERAS 6
- Target Price
- ALRS $25.30
- ERAS $4.83
- AVG Volume (30 Days)
- ALRS 95.5K
- ERAS 796.3K
- Earning Date
- ALRS 07-28-2025
- ERAS 08-12-2025
- Dividend Yield
- ALRS 3.89%
- ERAS N/A
- EPS Growth
- ALRS 350.15
- ERAS N/A
- EPS
- ALRS 1.59
- ERAS N/A
- Revenue
- ALRS $252,130,000.00
- ERAS N/A
- Revenue This Year
- ALRS $40.80
- ERAS N/A
- Revenue Next Year
- ALRS $3.69
- ERAS N/A
- P/E Ratio
- ALRS $13.56
- ERAS N/A
- Revenue Growth
- ALRS 53.68
- ERAS N/A
- 52 Week Low
- ALRS $15.78
- ERAS $1.01
- 52 Week High
- ALRS $24.41
- ERAS $3.31
- Technical
- Relative Strength Index (RSI)
- ALRS 50.55
- ERAS 58.30
- Support Level
- ALRS $20.33
- ERAS $1.38
- Resistance Level
- ALRS $22.19
- ERAS $1.71
- Average True Range (ATR)
- ALRS 0.70
- ERAS 0.11
- MACD
- ALRS 0.07
- ERAS 0.01
- Stochastic Oscillator
- ALRS 35.83
- ERAS 78.95
About ALRS Alerus Financial Corporation
Alerus Financial Corp is a financial holding company registered in the United States. The company operates in four segments: Banking, Retirement & Benefit Services, Wealth Management, and Mortgage. It provides various banking services such as checking, debit cards, savings, current deposits, loans and advances, online banking, mobile banking, private banking, payment solutions, and other business products. Additionally, the company provides mortgage loans, retirement planning solutions, individual retirement accounts, retirement plan advisory services as well as wealth management services, including financial & estate planning, trust, and fiduciary services. The company's revenue mainly consists of interest income, commission, management fees, and other income.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.